ASO GROUP Ltd Invests $2.75 Million in Becton, Dickinson and Company $BDX

ASO GROUP Ltd purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 14,152 shares of the medical instruments supplier’s stock, valued at approximately $2,746,000. Becton, Dickinson and Company accounts for about 1.1% of ASO GROUP Ltd’s investment portfolio, making the stock its 15th biggest position.

Other large investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in shares of Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after purchasing an additional 5,174,944 shares during the period. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after buying an additional 4,223,149 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock worth $769,397,000 after buying an additional 4,137,888 shares during the period. Norges Bank acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth $734,321,000. Finally, First Eagle Investment Management LLC boosted its position in shares of Becton, Dickinson and Company by 16.5% in the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after buying an additional 1,651,592 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $151.48, for a total transaction of $166,628.00. Following the completion of the sale, the executive vice president owned 14,272 shares in the company, valued at approximately $2,161,922.56. The trade was a 7.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $16,122,355.05. The trade was a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,013 shares of company stock valued at $593,434 in the last quarter. Corporate insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on BDX. Piper Sandler cut their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Evercore lifted their price objective on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Stifel Nicolaus dropped their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. The Goldman Sachs Group decreased their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Finally, Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $183.64.

Becton, Dickinson and Company Stock Down 0.3%

Shares of BDX opened at $147.40 on Friday. The company has a market capitalization of $40.62 billion, a P/E ratio of 37.32, a PEG ratio of 10.46 and a beta of 0.22. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The business’s 50 day simple moving average is $150.21 and its 200-day simple moving average is $174.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter in the previous year, the company posted $3.35 EPS. Becton, Dickinson and Company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.